Linda R. Duska, MD, MPH / Debra L. Richardson, MD, FACS, FACOG - Upgrading the Treatment Algorithm for Advanced Ovarian Cancer: Expert Tips, Tools, and Patient Care Strategies for Making the Most of PARP Inhibitors Across the Disease Continuum

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/UNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this discussion-based activity, two experts on ovarian cancer discuss the role of PARP inhibitors in treating advanced ovarian cancer. Upon completion of this activity, participants should be better able to: Adapt workflows to ensure that patients with ovarian cancer are receiving timely and appropriate genetic testing for BRCA, HRD, and other mutations that can help determine the role of PARP inhibitor therapy; Cite current efficacy and safety evidence on PARP inhibitors in different populations of patients with ovarian cancer; Utilize PARP inhibitors in the appropriate management of patients with ovarian cancer, including within the context of clinical trials, in accordance with current clinical evidence, guideline recommendations, mutation status, and patient needs and preferences; and Employ collaborative strategies to recognize and manage adverse events related to PARP inhibitor use in patients with ovarian cancer